Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension.
暂无分享,去创建一个
[1] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[2] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[3] S. Archer,et al. Oral Sildenafil Is an Effective and Specific Pulmonary Vasodilator in Patients With Pulmonary Arterial Hypertension Comparison With Inhaled Nitric Oxide , 2002 .
[4] W. Seeger,et al. Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension , 2002, Annals of Internal Medicine.
[5] R. Barst,et al. Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.
[6] L. Rubin,et al. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. , 2002, American journal of respiratory cell and molecular biology.
[7] R. Ewert,et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.
[8] R. Lookstein,et al. Flolan infusion interruption: a lethal complication during venous access. , 2001, Journal of vascular and interventional radiology : JVIR.
[9] F. Sakamaki,et al. Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy , 2000, Circulation.
[10] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[11] B. Groves,et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. , 1999, Circulation.
[12] S. Rich,et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.
[13] L. Rubin,et al. Primary pulmonary hypertension. , 1997, The New England journal of medicine.
[14] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[15] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.